J&J | JNJ - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Abbott USD 9.31B 104M 2026-03
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Bayer EUR 9.88B 452M 2026-03
Becton, Dickinson and Co. USD 24.13B 19.54B 2026-03
Biogen USD 1.96B 69.6M 2026-03
Boston Scientific USD 4.15B 107M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
CONMED USD 291.63M 44.94M 2026-03
Cooper Companies USD 1.11B 301.2M 2026-03
Dexcom USD 936.6M 0 2026-03
Edwards Lifesciences USD 1.13B 65.4M 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Globus Medical USD 595.85M 49.26M 2026-03
Insulet USD 639.7M 2.2M 2026-03
Integra LifeSciences USD 1.04B 673.49M 2026-03
Intuitive Surgical USD 1.91B 89.8M 2026-03
J&J USD 17.44B 1.53B 2026-03
Medtronic USD 7.72B 436M 2026-03
Merck USD 18.17B 8.01B 2026-03
Merit Medical Systems USD 337.72M 2.02M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Stryker USD 4.92B 284M 2026-03
Tandem Diabetes Care USD 282.09M 9.97M 2025-12
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Zimmer Biomet Holdings USD 1.69B 249.3M 2026-03
Zoetis USD 3.23B 1.68B 2026-03